1. Plecko, Barbara, Paul, Karl, Mills, Philippa, Abela, Lucia, Hofer, Doris. 2014. Pyridoxine responsiveness in novel mutations of the PNPO gene. In Neurology, 82, 1425-33. doi:10.1212/WNL.0000000000000344. https://pubmed.ncbi.nlm.nih.gov/24658933/
2. Deng, Zhendong, Sun, Shanliang, Zhou, Nian, Yang, Ye, Gu, Chunyan. 2024. PNPO-Mediated Oxidation of DVL3 Promotes Multiple Myeloma Malignancy and Osteoclastogenesis by Activating the Wnt/β-Catenin Pathway. In Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12, e2407681. doi:10.1002/advs.202407681. https://pubmed.ncbi.nlm.nih.gov/39656865/
3. Song, Hongwei, Ueno, Shu-ichi, Numata, Shusuke, Itakura, Mitsuo, Ohmori, Tetsuro. 2007. Association between PNPO and schizophrenia in the Japanese population. In Schizophrenia research, 97, 264-70. doi:. https://pubmed.ncbi.nlm.nih.gov/17851041/
4. Li, Xin, Guan, Wencai, Liu, Huiqiang, Zhang, Lingyun, Xu, Guoxiong. 2024. Targeting PNPO to suppress tumor growth via inhibiting autophagic flux and to reverse paclitaxel resistance in ovarian cancer. In Apoptosis : an international journal on programmed cell death, 29, 1546-1563. doi:10.1007/s10495-024-01956-3. https://pubmed.ncbi.nlm.nih.gov/38615082/
5. Jaeger, B, Abeling, N G, Salomons, G S, Geukers, V G, Poll-The, B T. 2016. Pyridoxine responsive epilepsy caused by a novel homozygous PNPO mutation. In Molecular genetics and metabolism reports, 6, 60-3. doi:10.1016/j.ymgmr.2016.01.004. https://pubmed.ncbi.nlm.nih.gov/27014579/
智鼠故事 
